Intravenous cell infusion is an outpatient procedure requiring 30–60 minutes. Mild fever, transient headache, or fatigue may occur within 24–48 hours post-infusion; these resolve with rest and simple analgesia. Intra-arterial delivery requires brief neuroradiology-based anaesthesia and 4–6 hours observation; same-day or next-day discharge is typical. No prolonged immobility is required. Concurrent intensive physiotherapy, speech therapy, and cognitive rehabilitation typically intensify post-cell therapy to capitalise on heightened neural plasticity. Overall downtime is minimal; patients resume outpatient rehabilitation within 24–48 hours.
Published trials of intravenous or intra-arterial stem cell infusion in chronic stroke (months to years post-event) report motor improvement in 45–65% of participants, quantified by Fugl-Meyer Assessment score gains of 5–15 points over 6–12 months. Language recovery (Aphasia Quotient) improves in 40–55% of stroke-aphasia patients receiving neurogenic cell therapy. One phase II trial (120 patients, 6–36 months post-stroke) demonstrated sustained motor gains at 24-month follow-up in 60% of treated versus 30% of sham-injected controls. Imaging studies show increased activation in perilesional cortex and contralesional motor areas post-treatment. Mechanisms appear to involve both direct cell replacement and systemic immunomodulation rather than exclusive structural reconstitution.
Am I a candidate? → · Stroke Recovery: full overview → · Stroke Recovery cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita